Metamark Inks Deal to Take Over Commercialization of Hologic Progensa Test | GenomeWeb

NEW YORK (GenomeWeb) – Metamark Genetics said today that it has signed a deal to become the exclusive worldwide sales agent for Hologic's Progensa PCA3 prostate cancer assay. The companies have also agreed to collaborate on a second-generation version of the test.

The Progensa test is designed to measure overexpression of prostate cancer antigen 3 (PCA3) RNA in urine samples and was cleared by the US Food and Drug Administration in 2012 for use on Hologic's semi-automated DTS system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.